Scholarlink

Background <p>Newborn screening (NBS) through disease biomarkers has significantly reduced severe outcomes of congenital disorders. Moreover, exploratory newborn genetic screening programs are increasingly being implemented. This consensus, developed by multidisciplinary experts, aims to standardize the combined screening of genes and biomarkers for neonatal diseases in China, balancing ethical, technical, and clinical considerations.</p> Data sources <p>This consensus synthesizes evidence from peer-reviewed literature (PubMed, CNKI, etc.) up to 2024 and integrates clinical experiences from multidisciplinary experts in neonatology, genetics, and laboratory medicine, focusing on disease biomarker-based NBS, newborn genetic screening, and the clinical utility of combined screening.</p> Results <p>The consensus defines principles for combined screening: (1) disease/gene selection: 154 disease-causing genes covering 67 inherited metabolic disorders (e.g., amino acid metabolism disorders, organic acid metabolism disorders), prioritized by treatability, onset age (&lt; 5&#xa0;years), and cost-effectiveness; (2) methodology: integrating dried blood spot biomarker analysis with next-generation sequencing-based targeted capture (coverage &gt; 300 ×), validated by MLPA/Sanger and long-range sequencing for complex variants (e.g., <i>CYP21A2</i>, <i>SLC25A13</i>); and (3) operational workflow: standardized workflows for informed consent, sample collection/delivery, and result interpretation, with dual reporting of marker and genetic findings within 15&#xa0;days. Positive cases require family verification and/or other genetic sequencing techniques.</p> Conclusions <p>This consensus establishes a practical framework for integrating marker and genetic screening, aiming to improve diagnostic accuracy and achieve rapid and effective interventions, thereby saving lives and reducing the occurrence of severe complications. Implementation requires interdisciplinary collaboration and ongoing quality control to maximize clinical utility.</p> Graphic abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Expert consensus on the combined screening of genes and biomarkers for neonatal diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月26日

查看全文
  • Xin-Wen Huang,
  • Ting Zhang,
  • Zhen-Zhen Hu,
  • Zhi-Guo Wang,
  • Xiao-Ping Luo,
  • Yan-Ling Yang,
  • Lian-Shu Han,
  • Xue-Fan Gu,
  • Guang-Ren Xiao,
  • Bao-Sheng Zhu,
  • Ru-Lai Yang,
  • Wei-Peng Wang,
  • Yong-Lan Huang,
  • Jian-Hui Jiang,
  • Hua Wang,
  • Guo-Li Tian,
  • Qiao-Ling Sun,
  • Xin-Mei Mao,
  • Bin Yu,
  • Wen-Bin Zhu,
  • Pi-Liang Chen,
  • Hai-Li Hu,
  • Hui-Ming Yan,
  • Jing Liu,
  • Wen-Ying Nie,
  • Feng Wang,
  • Ren Cai,
  • Tao Jiang,
  • Xiao-Hua Wang,
  • Fa-Liang Xu,
  • Yu-Lin Zhou,
  • Jian-Ping Yang,
  • Lin Zou,
  • Wei Wen,
  • Yuan-Yuan Kong,
  • Ming-Cai Ou,
  • Ya-Guo Zhang,
  • Yan-Qin Ying,
  • Rong Qiang,
  • De-Hua Zhao,
  • Chen-Lu Jia,
  • Zhi-Xin Zhang,
  • Ben-Qing Wu,
  • Hui Zou,
  • Zheng-Yan Zhao

摘要

Background

Newborn screening (NBS) through disease biomarkers has significantly reduced severe outcomes of congenital disorders. Moreover, exploratory newborn genetic screening programs are increasingly being implemented. This consensus, developed by multidisciplinary experts, aims to standardize the combined screening of genes and biomarkers for neonatal diseases in China, balancing ethical, technical, and clinical considerations.

Data sources

This consensus synthesizes evidence from peer-reviewed literature (PubMed, CNKI, etc.) up to 2024 and integrates clinical experiences from multidisciplinary experts in neonatology, genetics, and laboratory medicine, focusing on disease biomarker-based NBS, newborn genetic screening, and the clinical utility of combined screening.

Results

The consensus defines principles for combined screening: (1) disease/gene selection: 154 disease-causing genes covering 67 inherited metabolic disorders (e.g., amino acid metabolism disorders, organic acid metabolism disorders), prioritized by treatability, onset age (< 5 years), and cost-effectiveness; (2) methodology: integrating dried blood spot biomarker analysis with next-generation sequencing-based targeted capture (coverage > 300 ×), validated by MLPA/Sanger and long-range sequencing for complex variants (e.g., CYP21A2, SLC25A13); and (3) operational workflow: standardized workflows for informed consent, sample collection/delivery, and result interpretation, with dual reporting of marker and genetic findings within 15 days. Positive cases require family verification and/or other genetic sequencing techniques.

Conclusions

This consensus establishes a practical framework for integrating marker and genetic screening, aiming to improve diagnostic accuracy and achieve rapid and effective interventions, thereby saving lives and reducing the occurrence of severe complications. Implementation requires interdisciplinary collaboration and ongoing quality control to maximize clinical utility.

Graphic abstract